The B7–CD28 superfamily

被引:0
|
作者
Arlene H. Sharpe
Gordon J. Freeman
机构
[1] Immunology Research Divison,Department of Pathology
[2] Brigham,Department of Adult Oncology
[3] and Women's Hospital and Harvard Medical School,Department of Medicine
[4] Dana-Farber Cancer Institute,undefined
[5] Harvard Medical School,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The B7-1/B7-2–CD28/CTLA-4 co-stimulatory pathway has a crucial role in regulating T-cell activation and tolerance. New B7 and CD28 family members and new pathways have recently been identified that seem to be especially important for regulating the responses of previously activated, rather than antigen-inexperienced, T cells. B7-1 and B7-2 are expressed on professional antigen-presenting cells (APCs), with B7-2 being expressed earlier. B7-2 is more important than B7-1 in initiating T-cell responses. The new B7 homologues are also expressed on cells other than professional APCs, indicating that there might be new mechanisms for regulating T-cell responses in peripheral tissues. In contrast to the constitutive expression of CD28, the CD28 homologue ICOS is induced rapidly on T cells after TCR engagement. ICOS expression is stimulated by both TCR and CD28 signals. The ligand for ICOS (ICOSL) is expressed at low levels on resting B cells, some macrophages and dendritic cells, and can be induced by IFN-γ. ICOSL is also expressed on other cell types, including fibroblasts. Although the signals through CD28 are crucial for the initial co-stimulation of interleukin 2 (IL-2) production, ICOS signals only modestly influence T-cell proliferation and IL-2 production. ICOS signals are most important for regulating cytokine production by recently activated and effector T cells: ICOS can regulate both TH1 and TH2 effector cytokine production, and it has a particularly important role in regulating IL-10 production. ICOS has a crucial role in T-cell–B-cell collaboration and promotes immunoglobulin isotype class switching and germinal centre formation The CD28 family member PD-1 is inducibly expressed on T cells, B cells and myeloid cells, and has an ITIM/ITSM motif in its cytoplasmic domain that recruits SHP-2. PD-1-deficient mice develop late-onset progressive arthritis, lupus-like glomerulonephritis and myocarditis, showing that PD-1 has a role in downregulating immune responses. PD-1 binds to two B7 homologues, PD-L1 (B7-H1) and PD-L2 (B7-DC), but not to other B7 family members. The PD-1 ligands bind to PD-1 but no other CD28 family members. PD-L1 and PD-L2 are expressed in lymphoid and non-lymphoid tissues, and in some tumours. PD-L1 and PD-L2 can inhibit proliferation and cytokine production by previously activated T cells, and can antagonize a B7-2 signal when antigenic stimulation is weak or limiting. Like CTLA-4, PD-1 engagement can lead to cell cycle arrest. Some studies support a role for PD-L1 and PD-L2 in stimulating T-cell responses.
引用
收藏
页码:116 / 126
页数:10
相关论文
共 50 条
  • [41] Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation
    Salomon, B
    Bluestone, JA
    ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 : 225 - 252
  • [42] The regulation of plasma cell function through soluble mediators of the CD28/B7 pathway
    Holthausen, David
    Njau, Modesta
    Jacob, Joshy
    JOURNAL OF IMMUNOLOGY, 2013, 190
  • [43] EXPRESSION OF THE B7 AND ITS LIGAND CD28 IN HUMAN-MALIGNANT MELANOMA (MM)
    DIETRICH, A
    WUTTIG, C
    REICHEL, L
    VOITH, U
    HENNIG, B
    LEDBETTER, JA
    LINSLEY, PS
    VANSCHEIDT, W
    SCHOPF, E
    SIMON, JC
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1994, 102 (04) : 582 - 582
  • [44] Regulation of GVHD and graft-versus-leukemia (GVL) by CD28/B7 and CTLA-4/B7 interactions.
    Taylor, PA
    Vallera, DA
    Panoskaltsis-Mortari, A
    Sharpe, AH
    Blazar, BR
    BLOOD, 1998, 92 (10) : 434A - 435A
  • [45] CD28/B7 CORECEPTOR INTERACTION DURING THE DEVELOPMENT OF IMMUNITY TO HSV-1
    GEBHARDT, BM
    FASEB JOURNAL, 1995, 9 (03): : A529 - A529
  • [46] Control of memory CD4 T cell recall by the CD28/B7 costimulatory pathway
    Ndejembi, Modesta P.
    Teijaro, John R.
    Patke, Deepa S.
    Bingaman, Adam W.
    Chandok, Meena R.
    Azimzadeh, Agnes
    Nadler, Steven G.
    Farber, Donna L.
    JOURNAL OF IMMUNOLOGY, 2006, 177 (11): : 7698 - 7706
  • [47] B7/CD28-DEPENDENT AND B7/CD28-INDEPENDENT INDUCTION OF CD40 LIGAND EXPRESSION
    DING, L
    GREEN, JM
    THOMPSON, CB
    SHEVACH, EM
    JOURNAL OF IMMUNOLOGY, 1995, 155 (11): : 5124 - 5132
  • [48] CD28/B7 IN THE INDUCTION OF EFFECTOR FUNCTION AND ANERGY IN CD8+ T-CELLS
    HARDING, FA
    ALLISON, JP
    JOURNAL OF IMMUNOLOGY, 1993, 150 (08): : A258 - A258
  • [49] The effect of CD28/B7 blockade on alloreactive T and B cells after liver cell transplantation
    Reddy, B
    Gupta, S
    Chuzhin, Y
    Kalergis, AM
    Budhai, L
    Zhang, ML
    Droguett, G
    Horwitz, MS
    Chowdhury, JR
    Nathenson, SG
    Davidson, A
    TRANSPLANTATION, 2001, 71 (06) : 801 - 811
  • [50] Synergistic effect of CD40L/CD40 and CD28/B7 blockade in murine EAE
    Schaub, M
    Chandraker, A
    Sayegh, MH
    Khoury, SJ
    NEUROLOGY, 1997, 48 (03) : 6067 - 6067